CannabisNewsBreaks – Cannabis Global, Inc. (MCTC) Discusses Strong Solution with Expected 50%+ Cost Advantage in Production of THC-V and Other Rare Cannabinoids

June 3, 2020 10:43:28

Cannabis Global (OTC: MCTC), a cannabinoid and hemp extract science-forward company developing infusion and delivery technologies, today announced information on its Project Varin, a nearly complete research program implemented to develop novel production technologies for rare cannabinoids, including tetrahydrocannabivarin (“THC-V”), which is not scheduled at the federal level. According to the update, the program has produced meaningful technology breakthroughs resulting in several patent filings. The company has been able to leverage these technological developments to significantly reduce the cost of exotic cannabinoids on a per-serving basis resulting in a greater than 50% expected cost advantage. “We think we have rewritten the exotic cannabinoid cost equation via our Project Varin. The minor exotics represent a new cost challenge for the industry, and we believe we have developed a strong and defensible solution,” Arman Tabatabaei, CEO of Cannabis Global, stated in the news release. “Acquiring THC and CBD from plants within the Cannabaceae family is relatively easy as these cannabinoids are produced by nature in abundance. It is a very different issue relative to THC-V, CBN, and other exotics. With our patent pending technologies, we have been able to rewrite the cost equation for minor cannabinoids, while at the same time moving well beyond the purity possible from legacy technologies. While we are already at a 50% cost advantage to the competing technologies, most of which are still theoretical and not yet available on the market, we believe further travel down our cost curve is possible as we move into high volume manufacturing this month.”

To view the full press release, visit

About Cannabis Global, Inc.

Cannabis Global, Inc., formerly known as MCTC Holdings, Inc., is a fully audited and reporting company with the U.S. Securities & Exchange Commission, trading with the stock symbol MCTC. The company is an emerging force in the area of cannabinoid sciences and highly bioavailable hemp and cannabis infusion technologies. The company does not engage in the production, distribution, or sales of any controlled substances, including marijuana. The company has an actively growing portfolio of intellectual property having filed six patents in the areas of cannabinoid delivery systems and cannabinoid polymeric nanoparticles. The company markets its consumer products under the Hemp You Can Feel brand name. Cannabis Global launched is Project Varin early in 2020, to develop new delivery methods for rare cannabinoid Tetrahydrocannabivarin (“THC-V”) and to develop products based on this cannabinoid. For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to MCTC are available in the company’s newsroom at

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published:

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
303.498.7722 Office

CannabisNewsWire is part of the InvestorBrandNetwork.